Stock STSA SATSUMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from NASDAQ Composite Index CI
Satsuma Pharmaceuticals, Inc.(NasdaqGM:STSA) dropped from S&P TMI Index CI
Insider Buy: Satsuma Pharmaceuticals MT
Satsuma Pharmaceuticals, Inc. Announces CFO Changes CI
Satsuma Pharmaceuticals, Inc. Announces CEO Changes CI
Satsuma Pharmaceuticals, Inc. Announces Board Changes CI
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers. CI
Satsuma Pharmaceuticals' New Drug Application for Migraine Treatment Accepted for FDA Review MT
Satsuma Pharmaceuticals, Inc. Announces FDA Acceptance of 505(b)(2) New Drug Application for STS101 CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Sentiment -3- DJ
HC Wainwright Downgrades Satsuma Pharmaceuticals to Neutral From Buy MT
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals MT
Sector Update: Health Care Stocks Higher Premarket Monday MT
Bank Earnings in Focus as US Equity Futures Tread Water MT
Top Premarket Gainers MT
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical MT
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million. CI
Satsuma Pharmaceuticals Cash, Cash Equivalents and Marketable Securities Almost Halve to $52.5 Million at End of 2022 MT
Satsuma Pharmaceuticals Implements 36% Reduction in Workforce as Part of Cost-Cutting Program Shares Fall After Hours MT
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Satsuma Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Satsuma Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
North American Morning Briefing : Stock Futures -3- DJ

Chart Satsuma Pharmaceuticals, Inc.

Chart Satsuma Pharmaceuticals, Inc.
More charts

Company Profile

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.
Sector
Biotechnology & Medical Research
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
ARGENX SE Stock argenx SE
+1.02% 22.2B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
GENMAB A/S Stock Genmab A/S
-8.72% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. STSA Stock
  4. News Satsuma Pharmaceuticals, Inc.
  5. After Hours Watch List Scorecard: STSA, NOVN, CVAC